NCT06801236
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06801236
Title Phase 1 Study of ACE-232 to Treat Patients with Metastatic Castration-Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Acerand Therapeutics (Hong Kong) Limited
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of California San Diego, Moores Cancer Center RECRUITING La Jolla California 92093 United States Details
Moffitt Cancer Center, Tampa RECRUITING Tampa Florida 33612 United States Details
University of Maryland, Greenebaum Comprehensive Cancer Center NOT_YET_RECRUITING Baltimore Maryland 21201 United States Details
Harvard Medical School-Massachusetts General Hospital NOT_YET_RECRUITING Boston Massachusetts 02114 United States Details
M Health Fairview Clinics and Surgery Center RECRUITING Minneapolis Minnesota 55455 United States Details
Xcancer (Urology Cancer Center) RECRUITING Omaha Nebraska 68130 United States Details
Carolina Urologic Research Center RECRUITING Myrtle Beach South Carolina 29572 United States Details
Fred Hutchinson Cancer Research Center NOT_YET_RECRUITING Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field